Kornimate/medical-research-clean huggingface dataset:
diode laser 940 nm in management of loss of taste sensation

Conditions: SARS-CoV Infection

Summary: the global pandemic has recently emerged by transmission of sars-cov2 virus. the virus has had a massive impact on health, wealth and social aspects worldwide. since the identification of this virus in wuhan, china, millions of cases has been diagnosed worldwide with mortality rates ranging from 3% to 12 %

'long covid' is emerging as a phenomenon where patients have long-term unresolved symptoms (8,9). these could be prolonged symptoms of sars-cov2 or a postesars-cov2 syndrome for which dysfunction of smell and taste sensation has been proposed. the proposal presents the diode laser 940 as possible treatment for the loss of taste sensation in patients with long sars-cov2. the effect of low levels of laser energy was first discovered by dr endre mester in 1967.5 since then it has been used for various applications in the field of medicine and dentistry and is broadly termed 'low level laser therapy'(lllt) or 'biostimulation' or 'phototherapy'. it is defined as a 'non-thermal' laser light application using photons (light energy) from the visible and infrared spectrum for tissue healing and pain reduction (north american association of laser therapy-naalt). several in vitro studies have demonstrated that the effects of laser light on wound healing are much greater than obtained with light from other sources, such as light-emitting diodes (leds).(10-13)

Eligibility criteria:
inclusion criteria: a diagnosis of sars-cov2 with pcr. age range from 18-60 years old loss of taste sensation exclusion criteria: pregnancy or contraceptive pills lactation any auto-immune disease that could affect the oral mucosa on any neoplastic therapy. uncontrolled diabetes.

Keywords: sars-cov , loss of taste , diode laser
remotely resolving psychological stress (remote reps)

Conditions: Post Traumatic Stress Disorder

Summary: the investigators have developed a mobile app called resolving psychological stress (reps) for people with posttraumatic stress disorder (ptsd). the app will administer threat-related attention bias modification to individuals who score high on a ptsd checklist. this study will be administered remotely to individuals in the united states. the aims of the study are to explore feasibility, acceptability and usability of the app in an entirely remote study, as well as to explore the efficacy of the app at reducing attention bias and ptsd symptom severity.

posttraumatic stress disorder (ptsd) is a highly disabling disorder that affects approximately 8% of the population worldwide. threat-related attention biases represent an important mechanism that may underlie ptsd symptoms. such attention biases predict risk for ptsd following trauma exposure, and are thought to maintain some symptoms of ptsd. research indicates that specific forms of computerized attention bias modification (abm) training are effective in reducing attention bias for threat. we have developed a mobile app called reps (resolving psychological stress) to administer threat-related abm training to people with symptoms of ptsd and have tested it in a laboratory-based pilot study of 22 people with elevated ptsd symptoms. our preliminary data indicate that the app is highly acceptable to patients and that use of the app reduces attention bias for threat and ptsd symptom severity. the proposed study will expand on this prior lab-based study to test abm training on an app entirely remotely. our primary aim is to examine the feasibility, acceptability and usability of remotely administered app-based abm training and to determine the efficacy of remote app-based abm training in reducing attention bias and ptsd symptom severity. our secondary aim is to examine whether a personalized version of abm training results in greater attentional bias change and anxiety reduction compared to a non-personalized abm training.

Eligibility criteria:
inclusion criteria: * must own an ios device compatible with the app (i.e. iphones or ipod touches) * must score at or above 33 on ptsd checklist (pcl-5), which indicates clinically significant ptsd symptoms. exclusion criteria: * active suicidal ideation.

Keywords: ptsd attention bias modification remote app-based study digital health
sustained hbsag and viral response in patients achieved hbsag loss by interferon treatment

Conditions: Chronic Hepatitis B

Summary: chronic hepatitis b (chb) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (hcc).hbsag loss/seroconversion is considered to be the ideal endpoint of antiviral therapy in both hbeag-positive and hbeag-negative patients, as well as the ultimate treatment goal in chb. however, some patients who have achieved hbsag loss would reverse back to hbsag positive, or even become hbv reactive with recurrence of viremia. in current study, the viral and hbsag response in patients who have achieved hbsag loss by interferon (ifn) treatment will be observed for 96 weeks after the completion of ifn treatment. the primary analysis will be performed at the end of 96 weeks. following the completion of the study period of 96 weeks, patients will be offered to participate in a long term study for further observation of additional 144 weeks (total of 240 weeks from the enrollment).

chronic hepatitis b patients who have achieved hbsag loss from interferon treatment will be enrolled and observed for 96 weeks. serum hbv dna, hbsag, anti-hbs, hbeag, and anti-hbe will be measured every 3 months during the observation period. their liver function and chemistry tests are also performed every 3 months. the liver ultrasonic examination would be taken every 3-6 months. the primary measurement is the percentage of patients who have positive hbsag and/or a detectable level of hbv dna. following the completion of the study period, patients will be offered to participate in a long term study for further observation of additional 144 weeks.

Eligibility criteria:
inclusion criteria: * patients who had chronic hepatitis b and achieved hbsag loss by interferon treatment. exclusion criteria: * active consumption of alcohol and/or drugs * co-infection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus * history of autoimmune hepatitis * psychiatric disease * evidence of neoplastic diseases of the liver

Keywords: hbsag loss, interferon, hbv reaction
validation of the french version of the back belief questionnaire

Conditions: Back Pain Lower Back Chronic

Summary: the goal of this study is to carry out a transcultural validation of the back belief questionnaire in order to assess its appropriateness for french-speaking populations.


Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient has had back pain for at least 3 months exclusion criteria: * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant * the patient is breastfeeding
do nasogastric tubes after cardiac surgery reduce nausea and vomiting

Conditions: Heart Disease

Summary: gastric emptying is delayed after cardiac surgery, but the efficacy of the nasogastric (ng) tube in preventing distension and reducing vomiting is unclear. nasogastric (ng) tubes are routinely used in patients undergoing surgery. they are presumed to reduce postoperative nausea and vomiting (ponv) and to lessen the risk of aspiration by reducing residual gastric volumes; however, their insertion and use is not however without potentially serious complications. existing literature does not address their efficacy in reducing ponv after cardiac surgery. however, current evidence suggests that up to 50% of patients in this group suffer significant nausea and vomiting. the objective of this study is to determine whether ng tubes should continue to be inserted routinely during cardiac surgery to reduce ponv.


Eligibility criteria:
inclusion criteria: * undergoing coronary artery bypass graft and/or valvular surgery, * age 18-80 year olds * signed informed consent * elective or urgent surgery exclusion criteria: * past history of oesophageal surgery, oesophageal varices or stricture, * patients who have received antiemetic medication in the 24 hours before surgery * emergency surgery * patients that require re-sternotomy, or are not extubated 24 hours after admission to the intensive care unit, will be excluded from the study.

Keywords: nasogastric tubes nausea vomiting cardiac surgery
feasibility and patient reported tolerance of cryotherapy with the cooral ® mouth cooling device [mcd) in patients undergoing radiation therapy

Conditions: Oral Mucositis

Summary: this study is to investigate the use of the cooral ® standardized cyt device to achieve a constant and reproducible cooling of the oral mucosa to prevent om in patients undergoing rt in the head and neck region.

severe oral mucositis (som) is a major side-effect during (chemo)-radiation of malignancies of the head and neck. there is no standard management of som. previous studies have shown an effect of cryotherapy (cyt) on the incidence and duration of som in chemotherapy patients. especially in palliative cases it is necessary to keep treatment related morbidities low. due to the difficulties and possible side effects of ice chips (ic), a closed system, such as an intra oral mouth cooling device (mcd) might help to fully unfold the efficacy of cyt in the prevention of radiation therapy (rt)-induced oral mucositis (om), without putting the patient at risk for infections.the cooral ® system, provided by a swedish medical technology company free of charge, is composed of two parts: 1) the cooral ® system itself, which is a portable thermostat allowing to adjust temperatures , ranging between 6 and 22°c. 2) the mouthpiece composed of flexible plastic material (polyolefin polymer compound based on ethylene-vinyl acetate copolymer) that is connected via two flexible plastic hoses to the mouth cooling device (mcd). the water cooled inside the thermostat then circulates through the mouthpiece, allowing the mucosa to be cooled continuously and keep the desired temperature for any time. this study is to investigate the use of the cooral ® standardized cyt device to achieve a constant and reproducible cooling of the oral mucosa to prevent om in patients undergoing rt in the head and neck region.

Eligibility criteria:
inclusion criteria: * karnofsky performance score (kps) \>/= 60% * life expectancy \> 9 months * histologically proven malignant disease of the head and neck region * lntensity modulated radiationtherapy (imrt) radiotherapy * minimal dose to the oral mucosa \>/= 30 gy (eqd2 w. a/ß 2) * simultaneous use of mouthwashes is allowed if previously prescribed by the treating physician exclusion criteria: * history of severe oral mucositis (som) due to chemotherapy within the last 3 months * previous radiotherapy in the head-neck region * previous cryotherapy within the last 6 weeks * minimal doses \</=30 gy (eqd2 w. a/ß 2) * known history of ethylene-vinyl acetate allergy * simultaneous use of other forms of oral cryotherapy

Keywords: cooral ® mouth cooling device (mcd) cryotherapy radiation therapy severe oral mucositis head and neck cancer mouth cooling device
study of the safety, tolerability, pharmacokinetics and pharmacodynamic properties of oral at-406 in combination with daunorubicin and cytarabine in patients with poor-risk acute myelogenous leukemia (aml)

Conditions: Acute Myelogenous Leukemia (AML)

Summary: the main purpose of this study are to determine the maximum dose of at-406 that can be safely given in combination with cytarabine and daunorubicin to humans. other purposes are to determine how the drug is broken down in the body, and to see if there are any molecular interactions that can help determine how at-406 works. side effects will also be studied in an effort to make sure that this drug is safe to take.

this is an open label, multi-center, dose escalation study to determine the mtd of oral at-406 combined with daunorubicin and cytarabine in patients with poor-risk aml. treatment with at-406 will be administered to up to 60 patients at approximately 7 investigational sites in the us. patients will be enrolled in open label sequential cohorts of up to 12 patients to determine the mtd of at-406 in combination with daunorubicin and cytarabine. dose finding will occur during the induction cycle of the regimen. at-406 will not be administered in consolidation cycles. patients who require re-induction during initial treatment will be removed from the study and replaced (if needed) in order to assess at least 3 evaluable patients at each dose level. clinical and laboratory parameters will be assessed to evaluate the toxicity of at-406. in addition, pharmacokinetic (pk) and pharmacodynamic (pdy) blood samples will be analyzed for plasma concentrations and pdy effect of at-406, respectively.

Eligibility criteria:
eligibility criteria: inclusion: * male or females patients ages 18 to 74 * morphological diagnosis of untreated or relapsed non-m3 aml according to who diagnostic criteria who exhibit at least one poor-risk feature and are not be known to exhibit any favorable cytogenetic features or variants. * patients with relapsed aml and patients with prior autologous or allogeneic hematopoietic stem cell transplantations are eligible if relapse occurred following a remission of ≥ 6 months. * patients must have an ecog score of ≤ 2, * adequate cardiac, liver and renal function. exclusion: * must not have any evidence of cns leukemia.

Keywords: aml
1.2% rosuvastatin subgingivally delivered in chronic periodontitis with type 2 diabetes mellitus

Conditions: Chronic Periodontitis; Type2 Diabetes

Summary: the purpose of the present study was to evaluate the effects of subgingival delivery of 1.2% rosuvastatin (rsv) gel as an adjunct to scaling and root planing in chronic periodontitis (cp) with type 2 diabetes mellitus patients.

background: the purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of subgingival delivery of 1.2% rosuvastatin gel as an adjunct to scaling and root planing (srp) on clinical and radiographic parameters and compare this method with srp plus placebo gel alone in chronic periodontitis (cp) with type 2 dm patients. methods: eighty cp patients with type 2 dm are included in this study. they were divided into two groups: 1) srp + 1.2% rosuvastatin gel (rsv group); 2) srp + placebo gel (placebo group). at baseline, 3, 6 and 9 months after treatment, clinical measurements, including plaque index (pi), modified sulcus bleeding index (msbi), probing depth (pd), clinical attachment level (cal) and radiographic parameters intrabony defect depth (ibd), percentage change in radiographic defect depth reduction (ddr%) were assessed.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients with deep pockets (pd of ≥5mm or cal ≥4mm) and vertical bone loss ≥3 mm on intraoral periapical radiographs * patients with ≥20 teeth with no history of periodontal therapy in the preceding 6 months nor under any antibiotic therapy exclusion criteria: * patients with any other known systemic disease * patients on systemic statin therapy * known or suspected allergy to statin supplementation * patients with aggressive periodontitis * tobacco use in any form, smokers, alcoholics * immunocompromised patients * pregnant or lactating females
a study to evaluate cnto 1959 in the treatment of patients with moderate to severe plaque-type psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the efficacy and safety of cnto 1959 in the treatment of patients with moderate to severe plaque psoriasis.

this is a multicenter, dose-ranging study of cnto 1959 in patients with moderate to severe plaque psoriasis. patients who satisfy all inclusion and exclusion criteria will be assigned by chance to one of 7 treatment groups: a placebo group (a placebo is a treatment identical in appearance to cnto 1959 but does not contain active drug), 1 of 5 dose groups for cnto 1959, or adalimumab. patients assigned to adalimumab will be dosed according to the labeled dosing for psoriasis. at week 16, patients initially assigned to placebo will begin receiving cnto 1959. patients initially assigned to cnto 1959 will continue to receive the same assigned dose level of study agent from week 16 through week 40. patients receiving adalimumab will continue the labeled dosing regimen. all patients will be reassessed for clinical response every 4 weeks from week 4 through week 40. patients will continue dosing through week 40, with a subsequent efficacy and safety follow-up visit at week 52. patient safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months prior to first administration of any study agent * must be a candidate for phototherapy or systemic treatment for psoriasis (either new to treatment or having had previous treatment) * must be considered, in the opinion of the investigator, suitable candidates for adalimumab therapy * if a woman, she must be postmenopausal, or if premenopausal, she must be either surgically sterile, practicing a highly effective method of birth control, or not heterosexually active during the study and for 5 months after receiving the last dose of study drug * if a man, he must agree to use a double-barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study and for 5 months after receiving the last dose of study drug. exclusion criteria: * history of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease * has a contra-indication to anti-tnf therapy * has a history of chronic or recurrent infectious disease * has a nonplaque form of psoriasis or has drug-induced psoriasis * has been previously treated with adalimumab * has received any therapeutic agent directly targeted to il-12, il-17, or il-23, (including but not limited to ustekinumab, briakinumab \[abt-874\], ain457, and sch900222) within 6 months of the first administration of study agent.

Keywords: moderate to severe plaque-type psoriasis psoriasis plaque-type psoriasis cnto 1959 adalimumab
benefit of chemotherapy over best supportive care in metastatic and squamous cell-type esophageal cancer.

Conditions: Squamous Cell Carcinoma of Esophagus

Summary: interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("discontinuation design ")of patients with metastatic oesophageal cancer of squamous cell type the secondary aims would be to study : toxicity, the overall survival rate, a study of costs and quality of life.

as the data in litterature does not provide the basis for well-argued statistical hypothesis, it is suggested to randomize 30 patients per arm. an idmc will come to a decision after the inclusion of 10, 20 ans 40 patients on the efficacy and the toxicity profile and on whether to maintain the current clinical position, justifying randomisation . in order to take into account any possible effects of prior concomitant radiochemotherapy, patient will be stratified according to whether they have already undergone chemotherapy or radiochemotherapy.

Eligibility criteria:
inclusion criteria: * patients with an histologically proven epidermoid cancer of the oesophagus * patients with metastatic disease that can be measured or evaluated according to the recist criteria, and located outside of previously irradiated fields * patients who may or may not have undergone radiochemotherapy * patients who have not received chemotherapy for metastatic disease * ≥ 18 ans * performance status (ecog) ≤ 2 * people who are covered by private or state health insurance * informed consent signed by the patient exclusion criteria: * other evolutive malignant tumor * infection with hiv-1, hiv-2 or chronic hepatitis b or c * cerebral metastasis or known meningeal tumor * any unstable chronic diseases that could risk the safety or the compliance of te patient * women who are pregnant or breastfeeding. women must not breastfeed for at least 6 months after administration of bevacizumab * patients unable to undergo the follow-up of the trial for geographical, social or psychological reasons for the randomized part inclusion criteria : * non-progressive disease after the 6 first weeks of chemotherapy * performance status (ecog) ≤ 2

Keywords: chemotherapy best supportive care
open versus laparoscopic radical cystectomy

Conditions: Bladder Cancer

Summary: to date, no trials have been designed to compare open vs laparoscopic radical cystectomy in the elderly patients, both in terms of functional and clinical outcome measures. a more meaningful comparison of the two modalities is that of a randomized controlled trial.


Eligibility criteria:
inclusion criteria: 1. patients with a histologically proven diagnosis of transitional cell carcinoma of the bladder 2. patients with an indication to ureterocutaneostomy or ileal conduit 3. ecog performance status ≤ 2 4. wbc count ≥4,000/μl; platelet count ≥150,000/μl 4.recent (within 6 weeks of cystectomy) total body ct imaging study excluding distant metastases as well as upper urinary tract tcc exclusion criteria: 1. patients who have previously undergone lower abdominal and/or pelvic surgery for invasive cancer (i.e. radical prostatectomy, large bowel surgeries with or without ileal/colonic conduit) 2. patients who have previously received any pelvic irradiation 3. patients with a synchronous upper urinary tract malignancy requiring a nephroureterectomy concomitant to cystectomy 4. patients candidates for a palliative cystectomy (i.e. recurrent haematuria which cannot be treated by endoscopy) 5. patients with a histologically proven diagnosis of bladder adenocarcinoma, squamous cell carcinoma, and small cell carcinoma

Keywords: radical cystectomy laparoscopy